At variance3 with these findings, a recent study showed that deletion or pharmacological inhibition of calcium/calmodulin-dependent protein kinase 2 (CAMKK2) protects against prostate cancer development in preclinical mouse models lacking expression of prostate-specific PTEN [263]. Here, PTEN is linked to prostate carcinoma.